-+ 0.00%
-+ 0.00%
-+ 0.00%

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga·05/13/2025 17:06:46
Listen to the news

Gainers

  • HCW Biologics (NASDAQ:HCWB) stock increased by 173.1% to $14.23 during Tuesday's regular session. The market value of their outstanding shares is at $15.9 million.
  • Xilio Therapeutics (NASDAQ:XLO) shares increased by 40.75% to $1.03. The market value of their outstanding shares is at $53.2 million. As per the news, the Q1 earnings report came out 3 days ago.
  • CNS Pharma (NASDAQ:CNSP) shares rose 38.01% to $1.67. The market value of their outstanding shares is at $4.9 million.
  • Humacyte (NASDAQ:HUMA) stock moved upwards by 33.33% to $1.76. The market value of their outstanding shares is at $273.0 million. The company's, Q1 earnings came out today.
  • Apyx Medical (NASDAQ:APYX) stock moved upwards by 27.6% to $1.41. The market value of their outstanding shares is at $53.2 million. The company's, Q1 earnings came out 3 days ago.
  • Celularity (NASDAQ:CELU) stock moved upwards by 27.57% to $1.94. The company's market cap stands at $46.1 million. The company's, Q4 earnings came out 3 days ago.

Losers

  • Polyrizon (NASDAQ:PLRZ) stock decreased by 91.4% to $0.03 during Tuesday's regular session.
  • Zhengye Biotechnology (NASDAQ:ZYBT) shares declined by 64.03% to $4.83. The market value of their outstanding shares is at $228.9 million.
  • Accelerate Diagnostics (NASDAQ:AXDX) stock fell 38.48% to $0.08. The company's market cap stands at $2.0 million.
  • Regencell Bioscience (NASDAQ:RGC) stock decreased by 38.31% to $290.0. The company's market cap stands at $3.7 billion.
  • Sangamo Therapeutics (NASDAQ:SGMO) stock fell 36.51% to $0.47. The market value of their outstanding shares is at $106.5 million. As per the press release, Q1 earnings came out yesterday.
  • Halozyme Therapeutics (NASDAQ:HALO) stock decreased by 25.95% to $49.31. The market value of their outstanding shares is at $6.0 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.